Inhibition of anthrax lethal factor by curcumin and chemically modified curcumin derivatives

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 29, Issue 5, 2014, Pages 663-669

  Antonelli, Anthony C ^a   Zhang, Yu ^a   Golub, Lorne M ^a   Johnson, Francis ^a,b   Simon, Sanford R ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Chem Master International Inc   (United States)

Author keywords

Anthrax; Chemically modified curcumin; Curcumin; Lethal factor; Metalloproteinase

Indexed keywords

4 PHENYLAMINOCARBONYLBIS DEMETHOXYCURCUMIN; CHEMICALLY MODIFIED CURCUMIN; CURCUMIN; METALLOPROTEINASE; OLIGOPEPTIDE; UNCLASSIFIED DRUG; ANTHRAX TOXIN; BACTERIAL ANTIGEN; BACTERIAL TOXIN; ENZYME INHIBITOR;

ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BINDING AFFINITY; CATALYSIS; CHEMICAL MODIFICATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; LETHAL GENE; NONHUMAN; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOCATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BIOCATALYSIS; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84907044976     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2013.837901     Document Type: Article

References (27)

1. Mock M, Mignot T. Anthrax toxins and the host: a story of intimacy. Cell Microbiol 2003;5:15-23.
2. Brittingham KC, Ruthel G, Panchal RG, et al. Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis. J Immunol 2005;174:5545-52.
3. Rosenberger CM, Finlay BB. Phagocyte sabotage: disruption of macrophage signalling by bacterial pathogens. Nat Rev Mol Cell Biol 2003;4:385-96.
4. Dixon TC, Meselson M, Guillemin J, et al. Anthrax. N Engl J Med 1999;341:815-26.
5. Tonello F, Montecucco C. The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity. Mol Aspects Med 2009;30: 431-8.
6. Mastrolorenzo A, Supuran CT. Botulinus toxin, tetanus toxin, and anthrax lethal factor inhibitors. In: Supuran CT, Winum J-Y, eds. Drug design of zinc-enzyme inhibitors. Hoboken (NJ): John Wiley & Sons, Inc.; 2009:705-20.
7. Mock M, Fouet A. Anthrax. Ann Rev Microbiol 2001;55:647-71.
8. Brossier F, Mock M. Toxins of Bacillus anthracis. Toxicon 2001;39: 1747-55.
9. Ezzell Jr JW, Abshire TG. Serum protease cleavage of Bacillus anthracis protective antigen. J Gen Microbiol 1992;138: 543-9.
10. Abrami L, Liu S, Cosson P, et al. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J Cell Biol 2003;160:321-8.
11. Hellmich KA, Levinsohn JL, Fattah R, et al. Anthrax lethal factor cleaves mouse nlrp1b in both toxin-sensitive and toxin-resistant macrophages. PLoS ONE 2012;7:e49741.
12. Levinsohn JL, Newman ZL, Hellmich KA, et al. Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLoS Pathog 2012;8:e1002638.
13. Pannifer AD, Wong TY, Schwarzenbacher R, et al. Crystal structure of the anthrax lethal factor. Nature 2001;414:229-33.
14. Spyroulias GA, Galanis AS, Pairas G, et al. Structural features of angiotensin-I converting enzyme catalytic sites: conform-ational studies in solution, homology models and comparison with other zinc metallopeptidases. Curr Top Med Chem 2004;4: 403-29.
15. Popov SG, Popova TG, Hopkins S, et al. Effective antiprotease-antibiotic treatment of experimental anthrax. BMC Infect Dis 2005; 5:25.
16. Supuran CT, Scozzafava A, Clare BW. Bacterial protease inhibitors. Med Res Rev 2002;22:329-72.
17. Gupta SC, Prasad S, Kim JH, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 2011;28: 1937-55.
18. Zhang Y, Golub LM, Johnson F, et al. pKa, zinc-and serum albumin-binding of curcumin and two novel biologically-active chemically-modified curcumins. Curr Med Chem 2012;19:4367-75.
19. Ammon HP, Wahl MA. Pharmacology of curcuma longa. Planta Med 1991;57:1-7.
20. Kunwar A, Barik A, Mishra B, et al. Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim Biophys Acta 2008;1780:673-9.
21. Kocer SS, Walker SG, Zerler B, et al. Metalloproteinase inhibitors, nonantimicrobial chemically modified tetracyclines, and ilomastat block Bacillus anthracis lethal factor activity in viable cells. Infect Immun 2005;73:7548-57.
22. Zhang Y, Gu Y, Lee HM, et al. Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins. Curr Med Chem 2012;19: 4348-58.
23. Dell'Aica I, Dona M, Tonello F, et al. Potent inhibitors of anthrax lethal factor from green tea. EMBO Rep 2004;5:418-22.
24. Gaddis BD, Rubert Perez CM, Chmielewski J. Inhibitors of anthrax lethal factor based upon N-oleoyldopamine. Bioorg Med Chem Lett 2008;18:2467-70.
25. Numa MM, Lee LV, Hsu CC, et al. Identification of novel anthrax lethal factor inhibitors generated by combinatorial Pictet-Spengler reaction followed by screening in situ. ChemBioChem 2005;6: 1002-6.
26. Kochi SK, Schiavo G, Mock M, et al. Zinc content of the Bacillus anthracis lethal factor. FEMS Microbiol Lett 1994;124:343-8.
27. Ezzell JW, Ivins BE, Leppla SH. Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. Infect Immun 1984;45:761-7.